دورية أكاديمية
A possible usage of a CDK4 inhibitor for breast cancer stem cell-targeted therapy.
| العنوان: | A possible usage of a CDK4 inhibitor for breast cancer stem cell-targeted therapy. |
|---|---|
| المؤلفون: | Han YK; Research Center, Dongnam Institute of Radiological & Medical Sciences, Busan 619-953, Republic of Korea., Lee JH, Park GY, Chun SH, Han JY, Kim SD, Lee J, Lee CW, Yang K, Lee CG |
| المصدر: | Biochemical and biophysical research communications [Biochem Biophys Res Commun] 2013 Jan 25; Vol. 430 (4), pp. 1329-33. Date of Electronic Publication: 2012 Dec 19. |
| نوع المنشور: | Journal Article; Research Support, Non-U.S. Gov't |
| اللغة: | English |
| بيانات الدورية: | Publisher: Elsevier Country of Publication: United States NLM ID: 0372516 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1090-2104 (Electronic) Linking ISSN: 0006291X NLM ISO Abbreviation: Biochem Biophys Res Commun Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: <2002- >: San Diego, CA : Elsevier Original Publication: New York, Academic Press. |
| مواضيع طبية MeSH: | Breast Neoplasms/*therapy , Cyclin-Dependent Kinase 4/*antagonists & inhibitors , Neoplastic Stem Cells/*drug effects , Protein Kinase Inhibitors/*therapeutic use , Radiation Tolerance/*drug effects , Radiation-Sensitizing Agents/*therapeutic use, Apoptosis/drug effects ; Breast Neoplasms/radiotherapy ; Cell Cycle Checkpoints/drug effects ; Female ; Humans ; Molecular Targeted Therapy ; Neoplastic Stem Cells/radiation effects |
| مستخلص: | Cancer stem cells (CSCs) are one of the main reasons behind cancer recurrence due to their resistance to conventional anti-cancer therapies. Thus, many efforts are being devoted to developing CSC-targeted therapies to overcome the resistance of CSCs to conventional anti-cancer therapies and decrease cancer recurrence. Differentiation therapy is one potential approach to achieve CSC-targeted therapies. This method involves inducing immature cancer cells with stem cell characteristics into more mature or differentiated cancer cells. In this study, we found that a CDK4 inhibitor sensitized MDA-MB-231 cells but not MCF7 cells to irradiation. This difference appeared to be associated with the relative percentage of CSC-population between the two breast cancer cells. The CDK4 inhibitor induced differentiation and reduced the cancer stem cell activity of MDA-MB-231 cells, which are shown by multiple marker or phenotypes of CSCs. Thus, these results suggest that radiosensitization effects may be caused by reducing the CSC-population of MDA-MB-231 through the use of the CDK4 inhibitor. Thus, further investigations into the possible application of the CDK4 inhibitor for CSC-targeted therapy should be performed to enhance the efficacy of radiotherapy for breast cancer. (Copyright © 2012 Elsevier Inc. All rights reserved.) |
| المشرفين على المادة: | 0 (Protein Kinase Inhibitors) 0 (Radiation-Sensitizing Agents) EC 2.7.11.22 (Cyclin-Dependent Kinase 4) |
| تواريخ الأحداث: | Date Created: 20121225 Date Completed: 20130806 Latest Revision: 20130129 |
| رمز التحديث: | 20221213 |
| DOI: | 10.1016/j.bbrc.2012.10.119 |
| PMID: | 23261434 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 1090-2104 |
|---|---|
| DOI: | 10.1016/j.bbrc.2012.10.119 |